GLAXF
GSK plc
$25.70
0.00%
No data for this timeframe.
Vol
SEC Reports20
Recent Activity
May 20, 2026
SEC
GSK filed a 6-K reporting a routine director shareholding notification: Non-Executive Director Dr. Hal Barron acquired 7
6-K — Impact 2/10
May 20, 2026
SEC
GSK plc filed a Form 6-K disclosing an immaterial acquisition of 74 ADS by non-executive director Dr. Hal Barron at $49.
6-K — Impact 1/10
May 18, 2026
SEC
GSK announced that Japan's MHLW expanded approval of its RSV vaccine Arexvy to include adults aged 18-49 at increased ri
6-K — Impact 6/10
Analyst Ratings
5Strong Buy
8Buy
15Hold
4Sell
0Strong Sell
Latest Reports
NEUTRAL
6-K
2/10
GSK filed a 6-K reporting a routine director shareholding notification: Non-Executive Director Dr. Hal Barron acquired 7
May 20, 2026
NEUTRAL
6-K
1/10
GSK plc filed a Form 6-K disclosing an immaterial acquisition of 74 ADS by non-executive director Dr. Hal Barron at $49.
May 20, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
20 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 0 mixed, 16 neutral. Avg impact: 3.1/10.
NEUTRAL
6-K
2/10
GSK filed a 6-K reporting a routine director shareholding notification: Non-Executive Director Dr. H
May 20, 2026
NEUTRAL
6-K
1/10
GSK plc filed a Form 6-K disclosing an immaterial acquisition of 74 ADS by non-executive director Dr
May 20, 2026
BULLISH
6-K
6/10
GSK announced that Japan's MHLW expanded approval of its RSV vaccine Arexvy to include adults aged 1
May 18, 2026
NEUTRAL
6-K
2/10
GSK plc filed a Form 6-K reporting routine acquisitions of ordinary shares by multiple PDMRs (includ
May 14, 2026
NEUTRAL
6-K
2/10
GSK filed a 6-K reporting a routine PDMR transaction: Maya Martinez-Davis, President US, acquired 9.
May 11, 2026
NEUTRAL
6-K
4/10
GSK announced an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group) via its s
May 11, 2026
NEUTRAL
6-K
2/10
GSK announced the fifth and final tranche of its £2 billion share buyback programme, with up to appr
May 11, 2026
NEUTRAL
6-K
2/10
GSK held its 26th Annual General Meeting on May 6, 2026, with all 25 resolutions passed by a majorit
May 6, 2026
NEUTRAL
6-K
2/10
GSK granted a deferred investment award of notional ordinary shares to new Chief People Officer Roan
May 5, 2026
NEUTRAL
6-K
1/10
GSK plc disclosed its total voting rights as of 30 April 2026, reporting 4,316,202,660 issued shares
May 1, 2026
NEUTRAL
6-K
3/10
Dodge & Co filed a TR-1 notification disclosing a 4.93% voting rights stake in GSK plc as of April 2
May 1, 2026
NEUTRAL
6-K
2/10
GSK filed a Form 6-K reporting routine share transactions by two insiders: Independent Non-Executive
Apr 29, 2026
BULLISH
6-K
6/10
GSK reported Q1 2026 results with total turnover of £7.6 billion (+5% CER), Core operating profit up
Apr 29, 2026
NEUTRAL
6-K
2/10
GSK filed a Form 6-K reporting the vesting of a 2023 Performance Share Plan award for CFO Julie Brow
Apr 28, 2026
BULLISH
6-K
7/10
GSK announced FDA acceptance of its New Drug Application for bepirovirsen (chronic hepatitis B) with
Apr 28, 2026
BULLISH
6-K
7/10
GSK's investigational liver therapy, efimosfermin, has received FDA Breakthrough Therapy and EMA PRI
Apr 27, 2026
NEUTRAL
6-K
4/10
GSK subsidiary TESARO received a procedural court win as the Delaware Chancery Court dismissed Anapt
Apr 27, 2026
NEUTRAL
6-K
2/10
GSK plc filed a Form 6-K disclosing that Maya Martinez-Davis, President, US, acquired 8.572 American
Apr 24, 2026
NEUTRAL
6-K
3/10
GSK plc purchased 335,000 of its ordinary shares on April 21, 2026, at a volume-weighted average pri
Apr 22, 2026
NEUTRAL
6-K
3/10
GSK plc repurchased 330,000 ordinary shares on April 20, 2026, at a volume-weighted average price of
Apr 21, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 41% buy across 32 analysts — 5 strong buy, 8 buy, 15 hold, 4 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $8.2B | 3.1% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $8.9B | 3.7% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $33.8B | 3.4% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $35.4B | 4.8% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Apr 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Mar 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Feb 1, 2026 | 6 | 8 | 14 | 4 | 0 | 44% | |
| Jan 1, 2026 | 6 | 8 | 14 | 3 | 0 | 45% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.